$SYK has released its Q4 2024 earnings, reporting an EPS of $4.01, outperforming expectations by $0.14, and revenue of $6.44B, which reflects a 10.68% year-over-year growth. Key highlights include robust U.S. organic sales growth of 10.6%, driven by all major segments. However, ongoing risks include foreign currency impacts and potential challenges in the spinal implants division due to its divestiture.